Overview
Dr David Witty from the Witnet R&D Consultancy, formerly 91AV Director of Convergence Pharmaceuticals, is the sixth recipient of the BMCS Lectureship, awarded by the RSC's Biological and Medicinal 91AV. This, the first in a series of lectures to be delivered throughout the 2019/20 academic year, focuses on the future of Drug Discovery.
Medicinal 91AV is at the heart of Drug Discovery, but is often undervalued at a corporate level and has a surprisingly low visibility to the general public. Drawing from fifteen years' experience as editor of Progress in Medicinal 91AV, and over thirty years in Pharmaceutical R&D, this talk will look at which technologies and strategies have become embedded in the medicinal chemist's toolkit and which have failed or simply became passing trends. David will discuss how the role of the chemist has changed, what capabilities will be required of the drug designer in the next generation, and what advances we can aspire to achieve in the creation of new medicines.
Registration
The conference is free to attend, although registration is required via this weblink, https://events.rsc.org/rsc/1766/register. Registration will close on Tuesday, 29th October. Thereafter your name may be added to the waiting list.
Programme
18.00 Registration and light refreshments
18.30 Lecture
20.00 Close and depart
Dr David Witty from the Witnet R&D Consultancy, formerly 91AV Director of Convergence Pharmaceuticals, is the sixth recipient of the BMCS Lectureship, awarded by the RSC's Biological and Medicinal 91AV. This, the first in a series of lectures to be delivered throughout the 2019/20 academic year, focuses on the future of Drug Discovery.
Medicinal 91AV is at the heart of Drug Discovery, but is often undervalued at a corporate level and has a surprisingly low visibility to the general public. Drawing from fifteen years' experience as editor of Progress in Medicinal 91AV, and over thirty years in Pharmaceutical R&D, this talk will look at which technologies and strategies have become embedded in the medicinal chemist's toolkit and which have failed or simply became passing trends. David will discuss how the role of the chemist has changed, what capabilities will be required of the drug designer in the next generation, and what advances we can aspire to achieve in the creation of new medicines.
Registration
The conference is free to attend, although registration is required via this weblink, https://events.rsc.org/rsc/1766/register. Registration will close on Tuesday, 29th October. Thereafter your name may be added to the waiting list.
Programme
18.00 Registration and light refreshments
18.30 Lecture
20.00 Close and depart
